4.7 Article

Mild cognitive impairment in drug-naive patients with PD is associated with cerebral hypometabolism

Journal

NEUROLOGY
Volume 77, Issue 14, Pages 1357-1362

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e3182315259

Keywords

-

Funding

  1. Lundbeck Inc.
  2. Merck Serono
  3. Medivation, Inc.
  4. Boehringer Ingelheim
  5. Novartis
  6. UCB
  7. Solvay Pharmaceuticals, Inc.
  8. GE Healthcare
  9. GlaxoSmithKline
  10. Dia-Genic ASA
  11. Eisai Inc.

Ask authors/readers for more resources

Objective: To characterize brain metabolic changes associated with mild cognitive impairment (MCI) in drug-naive patients with Parkinson disease (PD) using (18)F-fluorodeoxyglucose (FDG) and PET (FDG-PET). Methods: This cross-sectional study included newly diagnosed patients with PD with MCI in single or multiple domain (PD-MCI; n = 12) and without MCI (PD-nMCI; n = 12), and healthy controls (n = 12). The groups were matched for age. Moreover, the patient groups were matched for motor disability. All subjects underwent a FDG-PET study. Cerebral regional relative metabolic maps were compared in PD-MCI, PD-nMCI, and controls using regions of interest analysis (ROIs) and voxel-based analysis with statistical parametric mapping. Results: ROIs and voxel-based analyses revealed significant relative hypometabolism in the prefrontal, superior/inferior parietal, and associative occipital cortices as well as in the striatum in patients with PD-MCI relative to controls (p < 0.05) and to a lesser extent in patients with PD-nMCI. In contrast, patients with PD-nMCI did not show significant metabolic changes as compared to controls. Conclusion: MCI in patients with PD is associated with cortical hypometabolism since the earliest stage, independent of therapy or motor disability. The early involvement of posterior cortical region, a pattern shared by advanced stages of PD-MCI and PD with dementia, could represent an early marker of dementia. The relevance of this pattern in predicting prodromal dementia has to be evaluated in longitudinal studies. Neurology (R) 2011;77:1357-1362

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available